155 related articles for article (PubMed ID: 12779088)
1. Androgen pathway dysregulation in BRCA1-mutated breast tumors.
Berns EM; Dirkzwager-Kiel MJ; Kuenen-Boumeester V; Timmermans M; Verhoog LC; van den Ouweland AM; Meijer-Heijboer H; Klijn JG; van der Kwast TH
Breast Cancer Res Treat; 2003 May; 79(1):121-7. PubMed ID: 12779088
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 mutations.
Pristauz G; Petru E; Stacher E; Geigl JB; Schwarzbraun T; Tsybrovskyy O; Winter R; Moinfar F
Histopathology; 2010 Dec; 57(6):877-84. PubMed ID: 21166701
[TBL] [Abstract][Full Text] [Related]
3. Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer.
Danzinger S; Tan YY; Rudas M; Kastner MT; Weingartshofer S; Muhr D; Singer CF
BMC Cancer; 2019 Jul; 19(1):695. PubMed ID: 31307407
[TBL] [Abstract][Full Text] [Related]
4. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
[TBL] [Abstract][Full Text] [Related]
5. Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers.
Aaltonen K; Blomqvist C; Amini RM; Eerola H; Aittomäki K; Heikkilä P; Nevanlinna H
Clin Cancer Res; 2008 Apr; 14(7):1976-83. PubMed ID: 18381935
[TBL] [Abstract][Full Text] [Related]
6. p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations.
Sensi E; Tancredi M; Aretini P; Cipollini G; Naccarato AG; Viacava P; Bevilacqua G; Caligo MA
Breast Cancer Res Treat; 2003 Nov; 82(1):1-9. PubMed ID: 14672397
[TBL] [Abstract][Full Text] [Related]
7. Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer.
Aloraifi F; Alshehhi M; McDevitt T; Cody N; Meany M; O'Doherty A; Quinn CM; Green AJ; Bracken A; Geraghty JG
Eur J Surg Oncol; 2015 May; 41(5):641-6. PubMed ID: 25736863
[TBL] [Abstract][Full Text] [Related]
8. Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes.
Loman N; Johannsson O; Bendahl PO; Borg A; Fernö M; Olsson H
Cancer; 1998 Jul; 83(2):310-9. PubMed ID: 9669814
[TBL] [Abstract][Full Text] [Related]
9. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.
Palacios J; Honrado E; Osorio A; Cazorla A; Sarrió D; Barroso A; Rodríguez S; Cigudosa JC; Diez O; Alonso C; Lerma E; Sánchez L; Rivas C; Benítez J
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3606-14. PubMed ID: 14506147
[TBL] [Abstract][Full Text] [Related]
11. The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer.
Tommiska J; Bartkova J; Heinonen M; Hautala L; Kilpivaara O; Eerola H; Aittomäki K; Hofstetter B; Lukas J; von Smitten K; Blomqvist C; Ristimäki A; Heikkilä P; Bartek J; Nevanlinna H
Oncogene; 2008 Apr; 27(17):2501-6. PubMed ID: 17982490
[TBL] [Abstract][Full Text] [Related]
12. Mutation analysis of BRCA1 and BRCA2 from 793 Korean patients with sporadic breast cancer.
Han SH; Lee KR; Lee DG; Kim BY; Lee KE; Chung WS
Clin Genet; 2006 Dec; 70(6):496-501. PubMed ID: 17100994
[TBL] [Abstract][Full Text] [Related]
13. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D
Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786
[TBL] [Abstract][Full Text] [Related]
14.
Lips EH; Debipersad RD; Scheerman CE; Mulder L; Sonke GS; van der Kolk LE; Wesseling J; Hogervorst FB; Nederlof PM
Clin Cancer Res; 2017 Mar; 23(5):1236-1241. PubMed ID: 27620280
[No Abstract] [Full Text] [Related]
15. BRCA-mutated Invasive Breast Carcinomas: Immunohistochemical Analysis of Insulin-like Growth Factor II mRNA-binding Protein (IMP3), Cytokeratin 8/18, and Cytokeratin 14.
Mohanty SK; Lai JP; Gordon OK; Pradhan D; Bose S; Dadmanesh F
Breast J; 2015; 21(6):596-603. PubMed ID: 26390986
[TBL] [Abstract][Full Text] [Related]
16. Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis.
Vaziri SA; Krumroy LM; Elson P; Budd GT; Darlington G; Myles J; Tubbs RR; Casey G
Clin Cancer Res; 2001 Jul; 7(7):1937-45. PubMed ID: 11448907
[TBL] [Abstract][Full Text] [Related]
17. Clinical implications for BRCA gene mutation in breast cancer.
Xu J; Wang B; Zhang Y; Li R; Wang Y; Zhang S
Mol Biol Rep; 2012 Mar; 39(3):3097-102. PubMed ID: 21691706
[TBL] [Abstract][Full Text] [Related]
18. Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families.
Eerola H; Heikkilä P; Tamminen A; Aittomäki K; Blomqvist C; Nevanlinna H
Breast Cancer Res; 2005; 7(4):R465-9. PubMed ID: 15987451
[TBL] [Abstract][Full Text] [Related]
19. Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia.
Spurdle AB; Couch FJ; Parsons MT; McGuffog L; Barrowdale D; Bolla MK; Wang Q; Healey S; Schmutzler R; Wappenschmidt B; Rhiem K; Hahnen E; Engel C; Meindl A; Ditsch N; Arnold N; Plendl H; Niederacher D; Sutter C; Wang-Gohrke S; Steinemann D; Preisler-Adams S; Kast K; Varon-Mateeva R; Ellis S; Frost D; Platte R; Perkins J; Evans DG; Izatt L; Eeles R; Adlard J; Davidson R; Cole T; Scuvera G; Manoukian S; Bonanni B; Mariette F; Fortuzzi S; Viel A; Pasini B; Papi L; Varesco L; Balleine R; Nathanson KL; Domchek SM; Offitt K; Jakubowska A; Lindor N; Thomassen M; Jensen UB; Rantala J; Borg Å; Andrulis IL; Miron A; Hansen TV; Caldes T; Neuhausen SL; Toland AE; Nevanlinna H; Montagna M; Garber J; Godwin AK; Osorio A; Factor RE; Terry MB; Rebbeck TR; Karlan BY; Southey M; Rashid MU; Tung N; Pharoah PD; Blows FM; Dunning AM; Provenzano E; Hall P; Czene K; Schmidt MK; Broeks A; Cornelissen S; Verhoef S; Fasching PA; Beckmann MW; Ekici AB; Slamon DJ; Bojesen SE; Nordestgaard BG; Nielsen SF; Flyger H; Chang-Claude J; Flesch-Janys D; Rudolph A; Seibold P; Aittomäki K; Muranen TA; Heikkilä P; Blomqvist C; Figueroa J; Chanock SJ; Brinton L; Lissowska J; Olson JE; Pankratz VS; John EM; Whittemore AS; West DW; Hamann U; Torres D; Ulmer HU; Rüdiger T; Devilee P; Tollenaar RA; Seynaeve C; Van Asperen CJ; Eccles DM; Tapper WJ; Durcan L; Jones L; Peto J; dos-Santos-Silva I; Fletcher O; Johnson N; Dwek M; Swann R; Bane AL; Glendon G; Mulligan AM; Giles GG; Milne RL; Baglietto L; McLean C; Carpenter J; Clarke C; Scott R; Brauch H; Brüning T; Ko YD; Cox A; Cross SS; Reed MW; Lubinski J; Jaworska-Bieniek K; Durda K; Gronwald J; Dörk T; Bogdanova N; Park-Simon TW; Hillemanns P; Haiman CA; Henderson BE; Schumacher F; Le Marchand L; Burwinkel B; Marme F; Surovy H; Yang R; Anton-Culver H; Ziogas A; Hooning MJ; Collée JM; Martens JW; Tilanus-Linthorst MM; Brenner H; Dieffenbach AK; Arndt V; Stegmaier C; Winqvist R; Pylkäs K; Jukkola-Vuorinen A; Grip M; Lindblom A; Margolin S; Joseph V; Robson M; Rau-Murthy R; González-Neira A; Arias JI; Zamora P; Benítez J; Mannermaa A; Kataja V; Kosma VM; Hartikainen JM; Peterlongo P; Zaffaroni D; Barile M; Capra F; Radice P; Teo SH; Easton DF; Antoniou AC; Chenevix-Trench G; Goldgar DE; ; ; ; ;
Breast Cancer Res; 2014 Dec; 16(6):3419. PubMed ID: 25857409
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer immunohistochemical features in young women with BRCA 1/2 mutations.
Zakhartseva LM; Gorovenko NG; Podolskaya SV; Anikusko NF; Lobanova OE; Pekur KA; Kropelnytskyi VA; Shurygina OV
Exp Oncol; 2009 Sep; 31(3):174-8. PubMed ID: 19877382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]